<DOC>
	<DOCNO>NCT00106522</DOCNO>
	<brief_summary>This 3 arm study compare safety efficacy , regard reduction sign symptom , tocilizumab versus placebo combination methotrexate ( MTX ) patient moderate severe active rheumatoid arthritis ( RA ) currently MTX therapy , inadequate response prior therapy anti-tumor necrosis factor ( anti-TNF ) agent . Patients randomize receive tocilizumab 4mg/kg iv , tocilizumab 8mg/kg placebo iv , every 4 week . All patient also receive methotrexate 10-25mg/week . The anticipated time study treatment 3-12 month , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Assess Effect Tocilizumab + Methotrexate Signs Symptoms Patients With Moderate Severe Active Rheumatoid Arthritis Currently Methotrexate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient least 18 year age moderate severe active RA least 6 month ; inadequate response current antirheumatic therapy , include MTX ; inadequate response intolerance treatment 1 antiTNF therapy within 1 year enter study ; stable MTX least 8 week enter study ; patient reproductive potential must use reliable method contraception . major surgery ( include joint surgery ) within 8 week screen , plan major surgery within 6 month enter study ; woman pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>